CER-1236 in Patients With Acute Myeloid Leukemia (AML)
Status:
RECRUITING
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
This is a rst in human, multi center, open label, phase 1/1b study to evaluate the safety and preliminary efcacy of CER-1236 in patients with relapsed/refractory (R/R), measurable residual disease (MRD) positive acute myeloid leukemia (AML), or TP53mut disease.